What began as a single explant case in 2018 ultimately changed the trajectory of my research into breast implant illness, biofilm, toxicity burden, and genetic detoxification pathways. After removing silicone gel implants from an ICU nurse who traveled from Louisiana for surgery, I identified a distinct sticky film coating the implant surfaces despite the implants appearing intact. Traditional cultures failed to identify significant bacterial growth, but the clinical findings strongly suggested chronic biofilm contamination. That experience led me to investigate PCR-based testing methods being explored during early research into Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Beginning in 2019, all explant specimens from my patients underwent PCR analysis through MicroGenDX, evaluating approximately 150 bacterial, fungal, and mycobacterial organisms. In 2024, we published the world’s largest PCR-tested breast implant illness capsule series consisting of 694 samples, revealing bacterial contamination in approximately 29% of cases, most commonly involving Staphylococcus epidermidis and Cutibacterium acnes.
Over time, it became increasingly clear that breast implant illness is likely multifactorial. Beyond biofilm and chronic inflammation, we identified major patterns involving environmental toxin exposure and impaired detoxification capability. Our internal audits demonstrated that approximately 83% of explant patients showed decreased detoxification function based
